Optimi Health Corp. (OPTH) announced on June 16, 2026, the completion of production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages, now available for authorized clinical research organizations. These new microdose formats extend Optimi's psilocybin range, which already includes a 5 mg formulation prescribed for treatment-resistant depression in Australia. The company's stock is trading at $4.57 (9.1% up) in after-hours trading, rebounding from a regular-session drop to $4.19.